| Literature DB >> 34007192 |
Jeremiah Seni1, Inyasi Lawrence Akaro2,3, Baraka Mkinze2,3, Zengo Kashinje1, Modest Benard1, Gerald Mboowa4, Dickson Aruhomukama4, Ivan Sserwadda4, Moses L Joloba4, Stephen E Mshana1, Benson R Kidenya5.
Abstract
BACKGROUND: The dual burden of road traffic accidents and antimicrobial resistance in orthopaedic infections is challenging already strained health-care systems. Limited information exists in Tanzania on antimicrobial resistance surveillance to delineate the potential sources of multi-drug-resistant bacteria for specific mitigation strategies among orthopaedic patients.Entities:
Keywords: ESBL colonization; Mwanza; Tanzania; orthopaedic patients
Year: 2021 PMID: 34007192 PMCID: PMC8123940 DOI: 10.2147/IDR.S303860
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Socio-Demographic and Clinical Characteristics of Index Orthopaedic Patients
| Variable | Number (%) | |
|---|---|---|
| Sex | Female | 87 (32.8) |
| Male | 178 (67.2) | |
| Residence | Rural | 68 (25.7) |
| Peri-urban | 62 (23.4) | |
| Urban | 135 (50.9) | |
| Education | No formal education | 20 (7.6) |
| Primary | 128 (48.3) | |
| Secondary | 70 (26.4) | |
| College and above | 47 (17.7) | |
| Occupation | Formal employment | 46 (17.4) |
| Unemployed | 86 (32.4) | |
| Business | 47 (17.8) | |
| Peasant | 86 (32.4) | |
| Referral status | Self-referral from home | 88 (33.2) |
| Referral from other hospital/clinic | 177 (66.8) | |
| Type of fracture | Closed | 184 (69.4) |
| Open | 73 (27.6) | |
| Both closed and open | 8 (3.0) | |
| Knowlege on antibiotics | No | 99 (37.4) |
| Yes | 166 (62.6) | |
| Heard about AMR | No | 132 (49.8) |
| Yes | 133 (50.2) | |
| Enough information on AMR | No | 225 (84.9) |
| Yes | 40 (15.1) | |
| Current antibiotic use | No | 164 (61.9) |
| Yes | 101 (38.1) | |
| History of antibiotic use* | No | 40 (15.1) |
| Yes | 225 (84.9) | |
| Self-treatment with antibiotics | No | 134 (50.6) |
| Yes | 131 (49.4) | |
| Domestic/pet animals at home | No | 128 (48.3) |
| Yes | 137 (51.7) | |
| Use of antibiotics in animals | No | 171 (64.5) |
| Yes | 94 (35.5) | |
| Heard of IPC | No | 30 (11.3) |
| Yes | 235 (88.7) | |
| Underlying diseases** | No | 242 (91.7) |
| Yes | 22 (8.3) | |
Notes: *In the past 3 months; **hypertension (n=9), HIV/AIDS (n=2), other cardiovascular conditions (n=3), diabetes mellitus (n=2), hypertension and diabetes mellitus (n=1), flu (n=1), asthma (n=1), osteomyelitis (n=1), peptic ulcer disease (n=1), and tumour of the leg (n=1).
Abbreviations: AMR, antimicrobial resistance; IPC, infection prevention and control.
Figure 1ESBL-producing Gram-negative bacteria from the orthopaedic index and neighbouring patients. *Others: Citrobacter spp. (2), Morganella morganii (2), and Pseudomonas aeruginosa (1).
Antimicrobial Susceptibility Patterns of ESBL-Producing Gram-Negative Bacteria Isolates
| Antimicrobial Agent | All Other Gram-Negative Bacteria** | ||||||
|---|---|---|---|---|---|---|---|
| Resistant, n (%) | Intermediate, n (%) | Sensitive, n (%) | Resistant, n (%) | Intermediate, n (%) | Sensitive, n (%) | ||
| Tetracycline | Index | 56 (75.7) | 4 (5.4) | 14 (18.9) | 36 (52.9) | 5 (7.4) | 27 (39.7) |
| Neighbour | 9 (81.8) | 1 (9.1) | 1 (9.1) | 4 (80.0) | 0 (0.0) | 1 (20.0) | |
| TMP-SXT | Index | 63 (85.1) | 1 (1.4) | 10 (13.5) | 65 (95.6) | 1 (1.5) | 2 (2.9) |
| Neighbour | 9 (81.8) | 1 (9.1) | 1 (9.1) | 5 (100.0) | 0 (0.0) | 0(0.0) | |
| Chloramphenicol | Index | 11 (14.9) | 0 (0.0) | 63 (85.1) | 21 (30.9) | 2 (2.9) | 45 (66.2) |
| Neighbour | 2 (18.2) | 0 (0.0) | 9 (81.8) | 1 (20.0) | 0(0.0) | 4 (80.0) | |
| Gentamicin | Index | 23 (31.1) | 3 (4.0) | 48 (64.9) | 28 (41.2) | 6 (8.8) | 34 (50.0) |
| Neighbour | 2 (18.2) | 0 (0.0) | 9 (81.8) | 1 (20.0) | 0(0.0) | 4 (80.0) | |
| Ciprofloxacin | Index | 38 (51.4) | 10 (13.5) | 26 (35.1) | 29 (42.6) | 15 (22.1) | 24 (35.3) |
| Neighbour | 8 (72.7) | 0 (0.0) | 3 (27.3) | 4 (80.0) | 0 (0.0) | 1 (20.0) | |
| Cefoxitin | Index | 12 (16.2) | 5 (6.8) | 57 (77.0) | 24 (35.3) | 3 (4.4) | 41 (60.3) |
| Neighbour | 2 (18.2) | 1 (9.1) | 8 (72.7) | 0 (0.0) | 0 (0.0) | 5 (100.0) | |
| Cefepime | Index | 72 (97.2) | 1 (1.4) | 1 (1.4) | 66 (97.1) | 2 (2.9) | 0 (0.0) |
| Neighbour | 11 (100.0) | 0 (0.0) | 0 (0.0) | 5 (100.0) | 0 (0.0) | 0 (0.0) | |
| TZP | Index | 8 (10.8) | 12 (16.2) | 54 (73.0) | 8 (11.8) | 10 (14.7) | 50 (73.5) |
| Neighbour | 1 (9.1) | 3 (27.3) | 7 (63.6) | 1 (20.0) | 0 (0.0) | 4 (80.0) | |
| Amikacin | Index | 0 (0.0) | 2 (2.7) | 72 (97.3) | 2 (2.9) | 0 (0.0) | 66 (97.1) |
| Neighbour | 0 (0.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 0 (0.0) | 5 (100.0) | |
| Meropenem | Index | 1 (1.4) | 1 (1.4) | 72 (97.2) | 6 (8.8) | 2 (2.9) | 60 (88.3) |
| Neighbour | 0 (0.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 0 (0.0) | 5 (100.0) | |
Notes: *Index isolates (n=74) and neighbours’ isolates (n=11); **index isolates (n=68) and neighbours’ isolates (n=5).
Abbreviations: TMP-SXT, trimethoprim–sulfamethoxazole; TZP, piperacillin–tazobactam.
Factors Associated with Gastrointestinal Tract ESBL Colonization Among Index Orthopaedic Patients
| Variable (N) | ESBL Colonization, n, (%) | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| 95% CI | 95% CI | ||||
| ≤18 (90) | 38 (42.2) | 1 | |||
| 19–59 (152) | 76 (50.0) | 1.37 (0.81–2.31) | 0.242 | ||
| ≥60 (23) | 11 (47.8) | 1.25 (0.50–3.14) | 0.629 | ||
| Female (87) | 47 (54.0) | 1 | |||
| Male (178) | 78 (43.8) | 0.66 (0.40–1.11) | 0.453 | ||
| Rural (68) | 33 (48.5) | 1 | |||
| Peri-urban (62) | 31 (50.0) | 1.06 (0.53–2.11) | 0.867 | ||
| Urban (135) | 61 (45.2) | 0.87 (0.49–1.57) | 0.652 | ||
| College and above (47) | 24 (51.1) | 1 | |||
| Informal (20) | 6 (30.0) | 0.41 (1.14–1.25) | 0.118 | 0.38 (0.12–1.22) | 0.105 |
| Primary (128) | 59 (46.1) | 0.82 (0.42–1.60) | 0.560 | 0.80 (0.40–1.61) | 0.532 |
| Secondary (70) | 36 (51.4) | 1.01 (0.48–2.12) | 0.969 | 1.02 (0.47–2.21) | 0.964 |
| Formal occupation (179) | 84 (46.9) | 1 | |||
| No formal occupation (86) | 41 (47.7) | 1.03 (0.62–1.72) | 0.909 | ||
| No (128) | 61 (47.7) | 1 | |||
| Yes (137) | 64 (46.7) | 0.96 (0.59–1.56) | 0.878 | ||
| Self-referral from home (88) | 36 (40.9) | 1 | |||
| From other hospital/clinic (177) | 89 (50.3) | 1.46 (0.87–2.45) | 0.151 | 1.44 (0.81–2.56) | 0.212 |
| Within 1 day (48) | 25 (52.1) | 1 | |||
| Up to 7 days (59) | 23 (39.0) | 0.59 (0.27–1.27) | 0.177 | 0.53 (0.24–1.16) | 0.113 |
| More than 7 days (60) | 26 (43.3) | 0.81 (0.38–1.72) | 0.576 | 0.92 (0.41–2.09) | 0.801 |
| Ward J5 (115) | 59 (51.3) | 1 | |||
| Ward E8 ((150) | 66 (44.0) | 0.75 (0.46–1.21) | 0.238 | ||
| Closed (184) | 78 (42.4) | 1 | |||
| Open (73) | 44 (60.3) | 2.06 (1.18–3.58) | 0.010 | 2.08 (1.56–3.75) | 0.015 |
| Both (8) | 3 (37.5) | 0.82 (0.19–3.51) | 0.784 | 0.55 (0.12–2.51) | 0.439 |
| No (40) | 15 (37.5) | 1 | |||
| Yes (225) | 110 (48.9) | 1.59 (0.80–3.18) | 0.186 | 1.97 (0.95–4.11) | 0.070 |
| No (164) | 76 (46.3) | 1 | |||
| Yes (101) | 49 (48.5) | 1.09 (0.66–1.79) | 0.731 | ||
| No (99) | 46 (46.5) | 1 | |||
| Yes (166) | 79 (47.6) | 1.04 (0.63–1.72) | 0.859 | ||
| No (132) | 60 (45.5) | 1 | |||
| Yes (133) | 65 (48.9) | 1.14 (0.71–1.86) | 0.577 | ||
| Yes (235) | 111 (47.2) | 1 | |||
| No (30) | 14 (46.7) | 0.98 (0.45–2.09) | 0.953 | ||
Notes: *The duration was missing in 98 patients; **in the past 3 months.
Abbreviations: AMR, antimicrobial resistance; ESBL, extended-spectrum beta-lactamase; IPC, infection prevention and control; CI, confidence interval.
Factors Associated with Occurrence of ESBL Bacteria in the Hospital Environment
| Variable (N) | ESBL Bacterial Contamination in the Hospital Environment, n, (%) | Univariate Analysis | |
|---|---|---|---|
| 95% CI | |||
| J5 (33) | 10 (30.3) | 1 | |
| E8 (53) | 17 (32.1) | 1.09 (0.42–2.78) | 0.863 |
| Walking crutches (11) | 1 (9.1) | 1 | |
| Wheelchair (13) | 4 (30.8) | 4.44 (0.42–47.5) | 0.217 |
| Bathroom sinks and door knobs (18) | 5 (27.8) | 3.85 (0.38–38.36) | 0.251 |
| Floor below patient’s bed (22) | 11 (50.0) | 10.0 (1.09–92.0) | 0.042 |
| Bed rails (22) | 6 (27.3) | 3.75 (0.39–35.9) | 0.252 |
| Round 1 on 16th January 2020 (29) | 12 (41.4) | 1 | |
| Round 2 on 28th March 2020 (28) | 12 (42.9) | 1.06 (0.37–3.04) | 0.910 |
| Round 3 on 28th May 2020 (29) | 3 (10.3) | 0.16 (0.04–0.67) | 0.012 |
Abbreviations: ESBL, extended-spectrum beta-lactamase; CI, confidence interval.